Welcome
to Brenus Pharma Learn more

Our vision

Brenus Pharma was founded some years ago by Jacques Gardette and Benoit Pinteur around predication shared on growing interest of immunotherapy in cancer treatments. They both supported the development of a autologous cell-based treatment now in a Phase 2 trial in US  for CNS cancer. Brenus Pharma was born when they figured out limits of autologous strategies to expand to industrialization scale and to access market.

By 2018, they moved Brenus Pharma to start investigations on its first cell-based Active Specific Immunotherapy, STC-1010.

STC-1010 acts on a synergistic add-on treatment with existing and coming therapeutic strategies. STC-1010 aims to stimulate patient’s own immune system bypassing tumour’s immunotolerance and drug resistance mechanisms occurring in solid cancers.

Founders have recently structured the company with a core multidisciplinary team composed of three executives highly skilled in life-cycle of biologics to support scientific, operational and business developments.

We are developing partnerships with academic renown experts in cancer and immunology to secure scientific and clinical development. We plan first patient to be treated by STC-1010 in a clinical Phase 1 trial setting by 2021.

Brenus Pharma

We target high unmet medical needs in oncology.

We position our offer in a center of a triangle made of Patient, Disease and oncologist. We stimulate patient’s own defense against his cancer, we help oncologist to keep control of disease along time with conventional treatments, and we aim to design easy manageable treatment to help compliance of patient to oncologist’s prescription.

We position our offer in a center of a triangle made of immune system, agressive tumour cells and chemo/radio/immunotherapies. We educate immune cells to recognise the widest panel of tumour antigens and limit immunoediting, we limit occurrence of chemoresistance, we aim to boost therapeutic strategies for a better control of tumor growth.

Our leadership

Founders have recently structured the company with a core multidisciplinary team composed of three executives highly skilled in life-cycle of biologics to support scientific, operational and business developments.
Jacques Gardette
Chief Executive Officer

J Gardette is the Chief Executive Officer of Brenus Pharma.

J Gardette is a visionary entrepreneur with 6 successful companies created, most of them in healthcare, either Biotech and Medtech.

He recently created Biocorp, innovative medtech pioneering in digital health with pharmaceutical or connected devices to help chronic diseases management. Biocorp is listed on Alternext.

With Dr Pinteur, he created Brenus Pharma to address uncovered medical needs in immunotherapy for resistant cancers, based on a breakthrough patented and scalable technology of Stimulated Tumor Cells.

Benoit Pinteur, Pharm D
Chief Scientific Officer in charge of the technical and pharmaceutical development of STC-1010 program

Dr. Pinteur is specialized in Advanced Therapy Medicinal Product development and particularly on cells and immunotherapies approaches. Co-Founder and Qualified Person of the CDMO Bio Elpida, Dr Pinteur has also strong knowledge on manufacturing and GMPs.

He has over 25 years of experience in the pharmaceutical industry including Schering-Plough, Roche Pharmaceuticals, Pierre Fabre.

He received his Doctor of Pharmacy with distinction from Joseph Fourier University at Grenoble in France.

Sebastien Petitet, MSc
Chief Commercial Officer in charge of the valorization of technology and products

Sebastien Petitet got key roles in European launchs of ATMP like 1st Triple in HIV, 1st MAB in colorectal cancer, 1st ERT, 1st Autologous Stem Cell therapy, and 1st Gene-therapy.

He acquired expertise within oncology and rare diseases area in Commercial, Medical and Market Access functions for GSK, Merck, Roche or Genzyme.

He passed MSc in Biochemistry at Medicine School of Clermont-Fd (France) and investigated digestive tract at TNO (The Netherlands).

Paul Bravetti, Pharm D, MSc.
Chief Operational Officer and is responsible for the company global development operations.

He is specialized in medical oncology and brings his strong experience in big pharma companies including Roche Pharmaceuticals, Servier International and Takeda Oncology, serving in both Medical Affairs, Marketing and Commercial functions. In his past experiences, Dr Bravetti led to successful launches of innovations in several disease areas including Melanoma, Lung cancer and Bio-molecular diagnosis across EU and Asia.

He received his Doctor of Pharmacy with a specialization in Clinical Oncology from Lorraine University in France and he completed his graduate work at HEC Paris achieving Master of Science degree in Intelligence Marketing.

Partners
& Collaborations

We are developing partnerships with academic renown experts in cancer and immunology to secure scientific and clinical development. We plan first patient to be treated by STC-1010 in a clinical Phase 1 trial setting by early 2022.
Manufacturing

BioElpida® : production Transcure® : a CRO specialized in full human immune system mouse disease models for cancer, infectious, inflammation and vaccines to move forward to close-to-human proof of efficacy and further characterization of mechanism of action

Transcure® : a CRO specialized in full human immune system mouse disease models for cancer, infectious, inflammation and vaccines to move forward to close-to-human proof of efficacy and further characterization of mechanism of action

Antineo®  : CRO specialized in POC in vivo in oncology

Financing

French Public investment bank for an application to a Financial Support to Innovation program.

Scientific and clinical experts

IRCM : Academic experts in Drug Resistance in CRC. To improve scientific characterization of its first therapeutic candidate, we are setting close collaborations with research team based in Montpellier (IRCM) focussing in colorectal cancer on:
– Transcriptome analysis to define signatures correlated with drug responses and identify new target.
– Synthetic lethality screening to identify new factors involved in chemoresistance in colorectal cancer
– Autophagy and mitophagy as a determinant of drug resistance in colorectal canc

Hospital of Lyon : early phase expert team, the academic staff of Pr Benoit You (part of CITOHL,Hospices Civiles de Lyon, France). This institution ran 169 clinical trials in 2018 with a focus on phase1 or phase2 trials.

Renape : French network for CRC with carcinosis